CN101006065B - 抑制bcl蛋白与结合伴侣的相互作用的化合物和方法 - Google Patents

抑制bcl蛋白与结合伴侣的相互作用的化合物和方法 Download PDF

Info

Publication number
CN101006065B
CN101006065B CN2005800281288A CN200580028128A CN101006065B CN 101006065 B CN101006065 B CN 101006065B CN 2005800281288 A CN2005800281288 A CN 2005800281288A CN 200580028128 A CN200580028128 A CN 200580028128A CN 101006065 B CN101006065 B CN 101006065B
Authority
CN
China
Prior art keywords
compound
alkyl
cancer
radical
aryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN2005800281288A
Other languages
English (en)
Chinese (zh)
Other versions
CN101006065A (zh
Inventor
A·C·喀斯特罗
W·邓
K·M·迪派
M·A·弗雷
C·C·弗里兹
A·T·乔吉斯伊凡格里诺斯
M·J·格罗甘
N·哈菲兹
E·B·霍尔森
B·T·霍普金斯
N·O·科奈
T·刘
D·A·曼
L·A·马库里尔
D·A·斯尼德
D·J·翁德伍德
A·A·惠尔
L-C·于
L·张
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Infinity Discovery Inc
Infinity Pharmaceuticals Inc
Original Assignee
Infinity Discovery Inc
Infinity Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Infinity Discovery Inc, Infinity Pharmaceuticals Inc filed Critical Infinity Discovery Inc
Publication of CN101006065A publication Critical patent/CN101006065A/zh
Application granted granted Critical
Publication of CN101006065B publication Critical patent/CN101006065B/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D261/18—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN2005800281288A 2004-06-17 2005-06-17 抑制bcl蛋白与结合伴侣的相互作用的化合物和方法 Expired - Fee Related CN101006065B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US58061604P 2004-06-17 2004-06-17
US60/580,616 2004-06-17
US65930105P 2005-03-07 2005-03-07
US60/659,301 2005-03-07
PCT/US2005/021524 WO2006009869A1 (en) 2004-06-17 2005-06-17 Coumpounds and methods for inhibiting the interaction of bcl proteins with binding partners

Publications (2)

Publication Number Publication Date
CN101006065A CN101006065A (zh) 2007-07-25
CN101006065B true CN101006065B (zh) 2012-07-11

Family

ID=35335774

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2005800281288A Expired - Fee Related CN101006065B (zh) 2004-06-17 2005-06-17 抑制bcl蛋白与结合伴侣的相互作用的化合物和方法

Country Status (21)

Country Link
US (1) US7851637B2 (enExample)
EP (1) EP1768966B1 (enExample)
JP (1) JP5064213B2 (enExample)
KR (1) KR101195351B1 (enExample)
CN (1) CN101006065B (enExample)
AT (1) ATE548359T1 (enExample)
AU (1) AU2005265131B2 (enExample)
BR (1) BRPI0511070A (enExample)
CA (1) CA2570780C (enExample)
EC (1) ECSP067099A (enExample)
ES (1) ES2382383T3 (enExample)
IL (1) IL179904A (enExample)
MA (1) MA28702B1 (enExample)
MX (1) MXPA06014754A (enExample)
NO (1) NO20070324L (enExample)
NZ (1) NZ552183A (enExample)
PL (1) PL1768966T3 (enExample)
PT (1) PT1768966E (enExample)
RU (1) RU2416606C2 (enExample)
WO (1) WO2006009869A1 (enExample)
ZA (1) ZA200610405B (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7842815B2 (en) * 2004-06-17 2010-11-30 Infinity Pharmaceuticals, Inc. Compounds and methods for inhibiting the interaction of BCL proteins with binding partners
CA2570780C (en) 2004-06-17 2013-12-03 Infinity Pharmaceuticals, Inc. Compounds and methods for inhibiting the interaction of bcl proteins with binding partners
US8624027B2 (en) 2005-05-12 2014-01-07 Abbvie Inc. Combination therapy for treating cancer and diagnostic assays for use therein
TWI403320B (zh) 2005-12-16 2013-08-01 Infinity Discovery Inc 用於抑制ｂｃｌ蛋白和結合夥伴間之交互作用的化合物及方法
TWI389895B (zh) 2006-08-21 2013-03-21 Infinity Discovery Inc 抑制ｂｃｌ蛋白質與結合夥伴間之交互作用的化合物及方法
EP1897956A1 (en) 2006-09-06 2008-03-12 Lonza AG Process for preparation of optically active amines by optical resolution of racemic amines employing a bacterial omega-transaminase
JP2011511076A (ja) * 2008-02-08 2011-04-07 エイルロン セラピューティクス，インコーポレイテッド 治療用ペプチド模倣大環状分子
US20110086834A1 (en) * 2008-06-26 2011-04-14 Amgen Inc. Alkynyl alcohols as kinase inhibitors
DK2321640T3 (en) 2008-08-21 2017-02-27 Immunogenics Llc FORMULATION FOR ORAL ADMINISTRATION OF PROTEINS
US8557983B2 (en) 2008-12-04 2013-10-15 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
US20100160322A1 (en) 2008-12-04 2010-06-24 Abbott Laboratories Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
UA108193C2 (uk) * 2008-12-04 2015-04-10 Апоптозіндукуючий засіб для лікування раку і імунних і аутоімунних захворювань
US8586754B2 (en) 2008-12-05 2013-11-19 Abbvie Inc. BCL-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases
CA2744711C (en) * 2008-12-05 2017-06-27 Abbott Laboratories Bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases
US8563735B2 (en) 2008-12-05 2013-10-22 Abbvie Inc. Bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases
US8546399B2 (en) * 2009-05-26 2013-10-01 Abbvie Inc. Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases
PE20120345A1 (es) * 2009-05-26 2012-05-17 Abbvie Bahamas Ltd Derivados de 2-(1h-pirrolo[2,3-b]piridin-5-iloxi)-n-fenilsulfonilbenzamida como inhibidores de proteinas anti-apoptoticas
US8314250B2 (en) 2009-11-24 2012-11-20 Hoffmann-La Roche Inc. Sultam derivatives
EP3099380B1 (en) 2014-01-28 2021-08-11 Buck Institute for Research on Aging Methods and compositions for killing senescent cells and for treating senescence-associated diseases and disorders
WO2015160975A2 (en) 2014-04-16 2015-10-22 Infinity Pharmaceuticals, Inc. Combination therapies
US10709692B2 (en) * 2015-12-04 2020-07-14 Denali Therapeutics Inc. Isoxazolidine derived inhibitors of receptor interacting protein kinase 1 (RIPK1)
NZ757763A (en) 2016-03-28 2025-07-25 Presage Biosciences Inc Pharmaceutical combinations for the treatment of cancer
WO2021233948A1 (en) 2020-05-19 2021-11-25 INSERM (Institut National de la Santé et de la Recherche Médicale) Method to treat a pathogen lung infection
EP4175644A1 (en) 2020-07-06 2023-05-10 Inserm (Institut National De La Sante Et De La Recherche Medicale) Combination of antineoplastic antibiotics and bcl-2 inhibitors for the treatment of npm-1-driven acute myeloid leukemia (aml)
WO2025087879A2 (en) 2023-10-23 2025-05-01 Institut National de la Santé et de la Recherche Médicale Suppressing the pi3kgamma/akt signalling pathway for the treatment of acute myeloid leukemia

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5686434A (en) * 1993-11-26 1997-11-11 Pfizer Inc. 3-aryl-2-isoxazolines as antiinflammatory agents
EP0970950A2 (en) * 1993-11-24 2000-01-12 DuPont Pharmaceuticals Company Novel isoxazoline and isoxazole fibrinogen receptor antagonists
US6747050B1 (en) * 1999-09-17 2004-06-08 Lg Chem Investment Ltd. Isoxazoline derivative and a process for the preparation thereof

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH445129A (fr) 1964-04-29 1967-10-15 Nestle Sa Procédé pour la préparation de composés d'inclusion à poids moléculaire élevé
US3459731A (en) 1966-12-16 1969-08-05 Corn Products Co Cyclodextrin polyethers and their production
US3426011A (en) 1967-02-13 1969-02-04 Corn Products Co Cyclodextrins with anionic properties
US3453257A (en) 1967-02-13 1969-07-01 Corn Products Co Cyclodextrin with cationic properties
US3453259A (en) 1967-03-22 1969-07-01 Corn Products Co Cyclodextrin polyol ethers and their oxidation products
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
JPS55133364A (en) * 1979-04-03 1980-10-17 Mitsubishi Petrochem Co Ltd Preparation of isoxazolidine derivative
US4737323A (en) 1986-02-13 1988-04-12 Liposome Technology, Inc. Liposome extrusion method
DE3643012A1 (de) * 1986-12-17 1988-06-30 Hoechst Ag 2,3-disubstituierte isoxazolidine, verfahren zu ihrer herstellung, diese enthaltende mittel und ihre verwendung
DE3829594A1 (de) * 1988-09-01 1990-03-15 Bayer Ag Neue renininhibitoren, verfahren zur herstellung und ihre verwendung in arzneimitteln
DE3926822A1 (de) * 1989-08-14 1991-02-21 Hoechst Ag Peptide mit bradykinin-antagonistischer wirkung
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
RU2142937C1 (ru) 1990-05-18 1999-12-20 Хехст АГ Амиды органических кислот, способ их получения и фармацевтическая композиция
US5294617A (en) 1993-04-23 1994-03-15 American Cyanamid Company Angiotensin II receptor blocking 2,3,6 substituted quinazolinones
US5849736A (en) * 1993-11-24 1998-12-15 The Dupont Merck Pharmaceutical Company Isoxazoline and isoxazole fibrinogen receptor antagonists
KR100200449B1 (ko) 1994-03-09 1999-06-15 디. 제이. 우드, 스피겔 알렌 제이 Tnf 방출 억제제로서의 이소옥사졸린 화합물
IL115849A0 (en) 1994-11-03 1996-01-31 Merz & Co Gmbh & Co Tangential filtration preparation of liposomal drugs and liposome product thereof
US5514505A (en) 1995-05-15 1996-05-07 Xerox Corporation Method for obtaining improved image contrast in migration imaging members
DE19539638A1 (de) 1995-10-25 1997-04-30 Hoechst Ag Die Verwendung von Isoxazol- und Crotonsäureamidderivaten zur Behandlung von Krebserkrankungen
US6221865B1 (en) * 1995-11-06 2001-04-24 University Of Pittsburgh Inhibitors of protein isoprenyl transferases
IT1283836B1 (it) 1996-08-28 1998-04-30 Viv Int Spa Procedimento per decorare profilati metallici,in materiale plastico e simili e relativa apparecchiatura
AU5239198A (en) 1996-10-16 1998-05-11 President And Fellows Of Harvard College, The Droplet assay system
AR015649A1 (es) * 1997-05-07 2001-05-16 Univ Pittsburgh Inhibidores de isoprenil-transferasas proteicas, composiciones que los comprenden y el uso de los mismos para la fabricacion de un medicamento
AU7105800A (en) 1999-09-01 2001-03-26 Chemrx Advanced Technologies, Inc. Process for synthesizing isoxazolidines
ES2349349T3 (es) 2001-05-30 2010-12-30 The Regents Of The University Of Michigan Asociacion sinergica de (-)-gosipol con docetaxel o paclitaxel para el tratamiento de cancer.
US20030119894A1 (en) 2001-07-20 2003-06-26 Gemin X Biotechnologies Inc. Methods for treatment of cancer or neoplastic disease and for inhibiting growth of cancer cells and neoplastic cells
FR2840807B1 (fr) 2002-06-12 2005-03-11 Composition cosmetique de soin et/ou de maquillage, structuree par des polymeres silicones et des organogelateurs, sous forme rigide
CA2570780C (en) 2004-06-17 2013-12-03 Infinity Pharmaceuticals, Inc. Compounds and methods for inhibiting the interaction of bcl proteins with binding partners

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0970950A2 (en) * 1993-11-24 2000-01-12 DuPont Pharmaceuticals Company Novel isoxazoline and isoxazole fibrinogen receptor antagonists
US5686434A (en) * 1993-11-26 1997-11-11 Pfizer Inc. 3-aryl-2-isoxazolines as antiinflammatory agents
US6747050B1 (en) * 1999-09-17 2004-06-08 Lg Chem Investment Ltd. Isoxazoline derivative and a process for the preparation thereof

Also Published As

Publication number Publication date
CA2570780C (en) 2013-12-03
NO20070324L (no) 2007-03-19
MXPA06014754A (es) 2007-06-22
RU2416606C2 (ru) 2011-04-20
PT1768966E (pt) 2012-05-23
ES2382383T3 (es) 2012-06-07
IL179904A0 (en) 2007-05-15
CN101006065A (zh) 2007-07-25
US7851637B2 (en) 2010-12-14
IL179904A (en) 2011-11-30
JP2008503489A (ja) 2008-02-07
ECSP067099A (es) 2007-04-26
JP5064213B2 (ja) 2012-10-31
KR20070046068A (ko) 2007-05-02
HK1105963A1 (en) 2008-02-29
MA28702B1 (fr) 2007-06-01
RU2007101276A (ru) 2008-08-10
KR101195351B1 (ko) 2012-10-29
CA2570780A1 (en) 2006-01-26
BRPI0511070A (pt) 2007-11-27
AU2005265131A1 (en) 2006-01-26
EP1768966A1 (en) 2007-04-04
EP1768966B1 (en) 2012-03-07
WO2006009869A1 (en) 2006-01-26
AU2005265131B2 (en) 2012-02-23
PL1768966T3 (pl) 2012-08-31
NZ552183A (en) 2009-10-30
ZA200610405B (en) 2008-03-26
US20060025460A1 (en) 2006-02-02
ATE548359T1 (de) 2012-03-15

Similar Documents

Publication Publication Date Title
CN101006065B (zh) 抑制bcl蛋白与结合伴侣的相互作用的化合物和方法
AU2007319848B2 (en) Compounds and methods for inhibiting the interaction of Bcl proteins with binding partners
CN101528716B (zh) 抑制bcl蛋白与结合伴侣的相互作用的化合物和方法
CN107223125B (zh) sGC刺激剂
CA2838223A1 (en) Fused benzoxazepinones as ion channel modulators
CN107406422A (zh) 作为sGC刺激剂的吡唑衍生物
CN111836812A (zh) sGC刺激剂的晶型
CN114008040A (zh) 用于调节fxr的化合物
HK1105963B (en) Compounds and methods for inhibiting the interaction of bcl proteins with binding partners
JP2004300145A (ja) 受容体拮抗剤
CN112079829A (zh) 1,2,4-三氮唑并[4,3-a]吡啶类衍生物及其制备方法和用途

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1105963

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20120711

Termination date: 20160617

CF01 Termination of patent right due to non-payment of annual fee